Limits...
Endocannabinoids modulate human blood-brain barrier permeability in vitro.

Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O'Sullivan SE - Br. J. Pharmacol. (2015)

Bottom Line: Endocannabinoids alter permeability at various epithelial barriers, and cannabinoid receptors and endocannabinoid levels are elevated by stroke, with potential neuroprotective effects.Anandamide (10 μM) and oleoylethanolamide (OEA, 10 μM) decreased BBB permeability (i.e. increased resistance).The endocannabinoids may play an important modulatory role in normal BBB physiology, and also afford protection to the BBB during ischaemic stroke, through a number of target sites.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK.

No MeSH data available.


Related in: MedlinePlus

The effects of AEA (n = 6) in the presence and absence of the FAAH inhibitor URB597 (n = 6) on permeability in the BBB (A), with corresponding AUC (B). Data are given as mean ± SEM. **P < 0.01, *P < 0.05 AEA versus the vehicle; ††P < 0.01 AEA and antagonist compared with AEA alone; one-way anova with Dunnett's test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4459020&req=5

fig03: The effects of AEA (n = 6) in the presence and absence of the FAAH inhibitor URB597 (n = 6) on permeability in the BBB (A), with corresponding AUC (B). Data are given as mean ± SEM. **P < 0.01, *P < 0.05 AEA versus the vehicle; ††P < 0.01 AEA and antagonist compared with AEA alone; one-way anova with Dunnett's test.

Mentions: Inhibition of the degradation of AEA by the fatty acid amide hydrolase (FAAH) inhibitor URB597 blocked the effects of AEA such that the change in TEER was no longer significantly different to that observed in the vehicle control inserts (Figure 3).


Endocannabinoids modulate human blood-brain barrier permeability in vitro.

Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O'Sullivan SE - Br. J. Pharmacol. (2015)

The effects of AEA (n = 6) in the presence and absence of the FAAH inhibitor URB597 (n = 6) on permeability in the BBB (A), with corresponding AUC (B). Data are given as mean ± SEM. **P < 0.01, *P < 0.05 AEA versus the vehicle; ††P < 0.01 AEA and antagonist compared with AEA alone; one-way anova with Dunnett's test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4459020&req=5

fig03: The effects of AEA (n = 6) in the presence and absence of the FAAH inhibitor URB597 (n = 6) on permeability in the BBB (A), with corresponding AUC (B). Data are given as mean ± SEM. **P < 0.01, *P < 0.05 AEA versus the vehicle; ††P < 0.01 AEA and antagonist compared with AEA alone; one-way anova with Dunnett's test.
Mentions: Inhibition of the degradation of AEA by the fatty acid amide hydrolase (FAAH) inhibitor URB597 blocked the effects of AEA such that the change in TEER was no longer significantly different to that observed in the vehicle control inserts (Figure 3).

Bottom Line: Endocannabinoids alter permeability at various epithelial barriers, and cannabinoid receptors and endocannabinoid levels are elevated by stroke, with potential neuroprotective effects.Anandamide (10 μM) and oleoylethanolamide (OEA, 10 μM) decreased BBB permeability (i.e. increased resistance).The endocannabinoids may play an important modulatory role in normal BBB physiology, and also afford protection to the BBB during ischaemic stroke, through a number of target sites.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK.

No MeSH data available.


Related in: MedlinePlus